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Abstract
Background: Centrosome amplification (CA) has been reported in nearly all types of human cancer and is
associated with deleterious clinical factors such as higher grade and stage. However, previous reports have not
shown how CA affects cellular differentiation and clinical outcomes in breast cancer.
Methods: We analyzed centrosomes by immunofluorescence and compared to ploidy and chromosomal instability
(CIN) as assessed by 6-chromosome FISH in a cohort of 362 breast cancers with median clinical follow-up of
8.4 years. Centrosomes were recognized by immunofluorescence using antibodies for pericentriolar material (PCM;
pericentrin) and centrioles (polyglutamylated tubulin). CA was experimentally induced in cell culture by
overexpression of polo-like kinase 4 (PLK4).
Results: CA is associated with reduced all-cause and breast cancer-specific overall survival and recurrence-free
survival. CA correlates strongly with high-risk subtypes (e.g. triple negative) and higher stage and grade, and the
prognostic nature of CA can be explained largely by these factors. A strong correlation between CA and high
tumor ploidy demonstrates that chromosome and centrosome doubling often occur in concert. CA is proposed to
be a method of inducing CIN via aberrant mitotic cell divisions; consonant with this, we observed a strong
correlation between CA and CIN in breast cancers. However, some CA tumors had low levels of CIN, indicating that
protective mechanisms are at play, such as centrosome clustering during mitosis. Intriguingly, some high-risk
tumors have more acentriolar centrosomes, suggesting PCM fragmentation as another mechanism of CA. In vitro
induction of CA in two non-transformed human cell lines (MCF10A and RPE) demonstrated that CA induces a de-
differentiated cellular state and features of high-grade malignancy, supporting the idea that CA intrinsically causes
high-grade tumors.
Conclusions: CA is associated with deleterious clinical factors and outcomes in breast cancer. Cell doubling events
are the most prevalent causes of CA in cancer, although PCM fragmentation may be a secondary cause. CA
promotes high-risk breast cancer in part by inducing high-grade features. These findings highlight the importance
of centrosome aberrations in the biology of human breast cancer.
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Background
The centrosome consists of a pair of attached centrioles
surrounded by proteinaceous pericentriolar material
(PCM) and functions as the major microtubule organiz-
ing center in human cells [1]. During interphase, centro-
somes organize cytoplasmic microtubules to control cell
shape, polarity, and motility; during mitosis, centro-
somes separate to form poles of the mitotic spindle.
Centrosome aberrations cause human diseases including
ciliopathies that arise from mutations in genes encoding
centrosome components, such as primary ciliary dyskin-
esia, autosomal recessive primary microcephaly, polycys-
tic kidney disease, and Bardet-Biedl disease [2].
Furthermore, structural and functional defects of centro-
somes are found in cancer, with the most commonly re-
ported being a numerical excess, known as centrosome
amplification (CA) [3].
Over a century ago, Theodor Boveri proposed that
supernumerary centrosomes can cause cancer [4]. In-
deed, CA and other centrosome defects have been re-
ported in diverse cancer types [3, 5]. In breast cancer,
centrosome aberrations are common, and amplification
correlates with higher tumor grade [6–8], metastasis
[9–11], and negative hormone receptor status [12, 13] in
small patient cohorts. Yet the causes and consequences
of CA in breast cancer remain obscure.
There are several major alternative mechanisms by
which CA can arise [3, 5], which we divide into three
categories: (1) cell doubling from cytokinesis failure,
cell-cell fusion, or endoreduplication resulting in both
genome and centrosome doubling; (2) centrosome dupli-
cation independent of cell doubling, either de novo or
due to dysregulation of the centriole cycle; and (3) PCM
fragmentation. The relative contributions of these mech-
anisms of CA to human breast cancer are unclear, but
can be addressed with a large cohort of tumor samples.
For instance, if polyploidy correlates with CA, this would
support genome doubling over centrosome duplication
or PCM fragmentation. Moreover, PCM fragmentation
is distinguished from duplication in that it is predicted
to cause acentriolar centrosomes. Here we evaluate these
to provide insight into mechanisms of CA in a large co-
hort of breast cancers.
The consequences of CA in human cancer also remain
unclear. CA is a key mechanism of chromosomal in-
stability (CIN), the perpetual gain or loss of whole chro-
mosomes during cell division. Cells with CA can
undergo asymmetric cell division with multipolar spin-
dles, resulting in CIN [6, 14, 15]. CIN leads to large
karyotypic diversity among cancer cells, and this genetic
diversity provides an enhanced opportunity for selection
of highly aggressive clones [16, 17]. Thus, CA can partly
explain the karyotypic diversity of breast cancer [18].
However, CA is unlikely to be necessary or sufficient for
CIN because CIN can arise from other pathways [19, 20].
Furthermore, cells with CA cluster centrosomes into a
pseudo-bipolar spindle under some conditions, allowing
them to avoid CIN induced by multipolar division [21].
Prior work has suggested CA is at least partly responsible
for CIN in a small cohort of breast cancers [22], but the
extent of CA as a cause of CIN is unknown.
In addition to CIN, CA can yield aggressive tumor
phenotypes via other mechanisms. For instance, CA
causes decreased cilia signaling, altered regulation of
Rho GTPases, and increased microtubule-directed
polarization [5, 23–25]. Furthermore, CA can behave
like an oncogene, increasing cell migration and invasive-
ness by enhancing Rac1 activity [13, 24]. These ideas
suggest that CA may directly promote tumor cell inva-
sion and metastasis without requiring altered genome
content. If these preclinical findings operate in human
breast cancer, then we would anticipate CA to correlate
with altered cancer cell physiology and worse clinical
outcomes, independent of CIN.
Here, we assess CA and other centrosome abnormal-
ities and correlate these with FISH data for 6 chromo-
somes and clinical outcomes in 362 human breast
cancers with a median 8.4 years of clinical follow-up.
We find that CA portends worse clinical outcomes, and
is most prevalent in high-risk breast cancer. The data
suggest that multiple mechanisms contribute to the de-
velopment of supernumerary centrosomes and that CA
promotes aneuploidy. There is a strong correlation be-
tween CA and tumor grade, providing a potential mech-
anism for the aggressive behavior of high-grade tumors.
Accordingly, in cell models, induced CA promotes ex-
pression of cellular markers of de-differentiation and in-
duces high-grade phenotypes. These findings provide
important insight into how CA arises and how it imparts
high-grade phenotypes and worse clinical outcomes in
human breast cancer. Moreover, our findings suggest
that pharmacologic interventions on CA or its down-
stream effects could improve outcomes for patients with
centrosome-amplified cancers.
Methods
Patients, tissues, ethics, and consent
The breast cancer tissue microarray (TMA) used in this
analysis has been described previously [26, 27]. Briefly,
samples were obtained from primary breast tumor
blocks obtained at time of surgery for stage I-III breast
cancer patients seen at the University of Wisconsin Car-
bone Cancer Center under protocol OS10111. The Uni-
versity of Wisconsin Health Sciences Institutional
Review Board approved the TMA creation and approved
use of the TMA and the de-identified coded data set
(IRB approval 2010-0405). This protocol retrospectively
collected de-identified data and archived tissue; the IRB
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waived patient consent. The TMA contains three
0.6 mm punch biopsies from each patient’s tumor, and
15 normal breast controls from mammoplasty are in-
cluded in the array. All cases had at least 5 years of
follow-up or recurrence or death within 5 years. Clinical
information includes age at diagnosis, ethnicity, tumor
size, lymph node involvement, stage, estrogen receptor
(ER), progesterone receptor (PR), and HER2 status, type
of surgery, adjuvant breast cancer treatments, and
follow-up data, including any recurrence and death.
Clinical data was obtained from the UW Hospital and
Clinics Cancer Registry and manual chart review. ER,
PR, and HER2 immunohistochemistry were also per-
formed on the completed TMAs and interpreted by a
breast pathologist. If ER/HER2 clinical data was not
available, the clinical pathologic data from the original
tumor sample was used for analysis. Patients with un-
known or equivocal values were excluded from these
analyses of subtype and CA. For subtype analysis, the
following groups were used based on their clinical rele-
vance [28, 29]: ER or PR positive and HER2-
nonamplified; HER2-amplified; and triple negative.
Immunohistochemistry
Breast cancer TMAs were sectioned at 5 μm thickness,
deparaffinized, and rehydrated. Antigen retrieval was
performed in a pressure cooker at 250 °F with citrate
buffer (pH 6) for 4 minutes. Blocking was done for
1 hour in 10 % fetal bovine serum (FBS) in PBS. Tissues
were probed with anti-pericentrin (Abcam, ab4448,
1:200) and anti-polyglutamylated tubulin (Adipogen,
GT335, 1:100) antibodies diluted in 1 % FBS and 0.1 %
triton X in PBS overnight in a humidified chamber at 4 °
C. Pericentrin and polyglutamylated tubulin are bona
fide markers of centrosomes [30–32]. The TMAs were
then incubated with anti-rabbit Alexa 488 and anti-
mouse IgG1 Alexa 647 secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA) for
1 hour at room temperature. Slides were washed 3 times
after primary and secondary antibody incubations. Slides
were counterstained for DNA with 4′,6-diamidino-2-
phenylindole (DAPI) and mounted with ProLong Gold
antifade reagent (Life Technologies). Scoring of centro-
some phenotypes was performed using a Nikon Eclipse
Ti inverted microscope, 100x objective, and CoolSNAP
HQ2 charge-coupled device camera (Photometrics). The
observer was blinded to clinical data and analyzed cen-
trosomes in a minimum of 30 cells per case from 3 dif-
ferent tumor regions. The number of distinct pericentrin
foci as well as foci that overlapped with polyglutamy-
lated tubulin were counted. Cell boundaries were visual-
ized by nonspecific background staining with the
polyglutamylated tubulin antibody. Average centrosome
number per cell was calculated for each case.
Centrosome sizes were measured in at least 15 represen-
tative centrosomes per case from three different tumor
regions using the pericentrin marker, and an average was
calculated for each case. For survival analysis, the me-
dian centrosome size (0.99 μm) was used as the cutoff
for large versus small centrosomes. In addition to num-
ber and size, we also noted any unusual centrosome
phenotypes such as centrosome clustering, centrosome
speckling, and atypical shapes.
A small fraction of samples in the TMA were not eva-
luable due to loss of tissue, insufficient cellularity, or
other technical issues and were excluded from analysis.
Centrosome data were linked to de-identified clinical
data by sample number and position on the TMA and
sorted for analysis using Microsoft Excel.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
using standard techniques, as reported elsewhere [33].
Briefly, chromosomes 4, 10, and 17 were probed on one
section, and chromosomes 3, 7, and 9 on another sec-
tion. Chromosomes were counted by observers blinded
to patient conditions in a minimum of 10 cells per case.
A small fraction of samples were not evaluable due to
loss of tissue, insufficient cellularity, or other technical
issues and were excluded from analysis. Similarly a sub-
set of samples had a single probe that was not well visu-
alized, but if at least five chromosomes were available, it
was included in further analyses. FISH data were linked
to de-identified clinical data by sample number and pos-
ition on the TMA and sorted for analysis using Micro-
soft Excel. Ploidy was determined by the average
chromosome number for all 6 probes combined. CIN
was determined as the average percentage of cells that
deviated from the modal number for each of the 6 chro-
mosomes assessed by FISH. Samples were considered to
have CIN if this value exceeded 45 %, a cutoff that
yielded appropriate percentages of normal samples and
tumors with CIN.
Cell culture
The doxycycline-inducible PLK4WT and PLK4608
MCF10A and RPE cell lines were a kind gift from Dr.
David Pellman. Cells were cultured and centrosome
amplification was induced as previously described [24,
33]. For assays, cells were treated with 2 μg/mL doxycyc-
line for 48 hours and subsequently harvested for qRT-
PCR and flow cytometry. Immunofluorescence was per-
formed as previously described using the following anti-
bodies: anti-pericentrin (Abcam, ab4448), anti-gamma
tubulin (Abcam, ab27074), anti-alpha tubulin (Millipore,
MAB1864), and Alexa fluorophore-conjugated second-
ary antibodies (Jackson).
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Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
RNA was isolated from cells using the RNeasy Micro Kit
(Qiagen, Valencia, CA), and converted to cDNA using
the Quantitect Reverse Transcription Kit (Qiagen). qRT-
PCR was performed using EvaGreen master mix (Mid-
Sci, St. Louis, MO) and a StepOne Plus instrument (Ap-
plied Biosystems). Quantification of cytokeratins 7, 18,
and 19 (KRT7, KRT8, KRT19) expressed as mRNA level
was normalized to the mRNA of three housekeeping
genes (RRN18S, GAPDH and ACTB). Primers sequences
are provided in Additional file 1: Table S3. Fold changes
in gene expression were assessed using the 2^-ΔΔCt
method [34].
Flow cytometry
A total of 50,000 events were acquired for each sample
using an Accuri C6 flow cytometer (Accuri, Ann Arbor,
MI) equipped with multicolor analysis, and data were
analyzed with Flow Jo 7.0 (Tree Star, Ashland, OR).
Samples were run in triplicate in at least 3 independent
experiments. The following antibodies were used: CD24-
PE, CD44-PE, and mouse IgG1 isotype control (BD Bio-
sciences). Mean channel fluorescence of FL2 was used to
quantitatively compare conditions.
Statistical analysis
R (version 3.1.1, R Core Team, Vienna, Austria) statis-
tical software was used for survival analysis. A total of
362 patients were included in survival analyses. The clin-
ical outcomes analyzed in this study were recurrence-
free survival (RFS) and overall survival (OS). RFS was
defined as the time from initial breast cancer diagnosis
to recurrence. OS was defined as the time from diagno-
sis to the date of death. RFS and OS were plotted using
the Kaplan–Meier method, and log-rank tests were used
to compare patients with tumors with CA versus tumors
with no CA using 2 centrosomes per cell as a cutoff.
Sensitivity analyses were also performed using the mean
and median of all the normal breast samples in the
TMA as the cutoff for defining CA. Cox proportional
hazards model included centrosome amplification, stage,
tumor grade, hormone receptor status, and HER2 status.
Associations between these factors and either RFS or OS
were analyzed and presented as hazard ratios (HR) with
95 % confidence intervals (CI). For centrosome size, an
average size was calculated for each case. The median of
all cases was used as the cutoff for the large versus small
centrosome groups. The correlations of CA with ploidy
and CIN were assessed with Spearman’s correlation. The
correlations between centrosome amplification and
grade or stage were performed by stratifying patients by
grade or stage and comparing the mean centrosome
number among the groups by Kruskal-Wallis tests. Non-
parametric tests were used because the distribution of
average centrosome number was right skewed (Add-
itional file 1: Figure S1). Two-sided, unpaired statistical
tests were used throughout. P < 0.05 was considered sta-
tistically significant for all statistical tests.
Results
Centrosome amplification is associated with adverse
clinical factors and worse survival
We initially characterized the distribution of centrosome
abnormalities and clinical characteristics seen in our
breast cancer samples. Patient characteristics are shown in
Additional file 1: Table S1. Centrosomes were assessed in
each sample using pericentrin, a PCM marker. The nor-
mal mammary gland is composed of terminal ductal lobu-
lar units, and polarity is well defined, as indicated by
luminal positioning of the centrosome and basal position-
ing of the nucleus (Fig. 1a, top). However, this
organization is disrupted in carcinoma samples (Fig. 1a,
bottom). Furthermore, the median centrosome number
from all the tumor samples was almost double that of the
normal breast samples (1.8 vs. 1.0, p = 0.001), and 84 %
(305 of 362) of breast cancer samples had a mean centro-
some value higher than that of the normal breast samples.
Additionally, the average centrosome number per cell and
the percent of cells with greater than 2 centrosomes were
both significantly greater in breast cancers compared to
normal breast (Fig. 1b-c). To demonstrate that this is not
simply due to a greater proliferative rate in the tumors (as
centrosomes are duplicated at the G1/S transition), we
correlated average centrosome number with Ki67, a
marker of proliferative index. Although there is a partial
correlation, a significant portion of samples have high
centrosome number with low Ki67 (Fig. 1d). Because of
the partial correlation, an elevated average centrosome
number between 1 and 2 could indicate an increase in the
percent of tumor cells in G2. Hence, we used a strict cut-
off of >2 centrosomes for subsequent analyses of CA.
Breast cancers also showed a wider distribution of mean
centrosome number per cell compared to normal breast
(range 0.5–5.9 and 0.23–2.77, respectively), consistent
with CA occurring in a variable fraction of cells within a
tumor. The distribution of centrosomes in breast cancer
was unimodal with right skew, while the distribution of
centrosomes in normal breast samples was normal (Add-
itional file 1: Figure S1).
We stratified patients based on stage, grade, subtype,
regional node status, and recurrence site. Patients with
higher stage and grade also had a higher average number
of centrosomes per cell (Fig. 2a-b). Furthermore, CA
was greater in triple negative and HER2 amplified sub-
types (Fig. 2c); in general, estrogen/progesterone
receptor-positive breast cancers have a more favorable
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prognosis than HER2 amplified or triple negative can-
cers [35].
A tumor was considered to have CA if the mean num-
ber of pericentrin foci per cell exceeded 2. Using this
definition, CA was found in 35.1 % of breast tumors and
13.3 % of normal breast samples. It was most common
in triple negative breast cancers (61.4 %) and less fre-
quent in HER2-positive (41.2 %) and hormone-sensitive/
HER2-negative subgroups (29.2 %). We next assessed
how CA correlated with clinical outcomes. Patients with
CA had significantly worse overall survival (OS, P =
0.002; Fig. 2d) and recurrence-free survival (RFS, P <
Fig. 1 Centrosome amplification in breast cancer. a Representative single plane images of normal breast and breast cancer from the TMA
taken using the 100x objective. Blue = DNA, green = pericentrin. Scale bar = 5 μm. b The average centrosome number per cell (as assessed by
pericentrin staining) is significantly greater in breast tumors than in normal breast samples included in the TMA (p = 0.0012 from unpaired, two-
tailed t-test). c The percentage of tumors with an average of > 2 centrosomes per cell is significantly greater than the percentage of normal breast
samples with > 2 centrosomes per cell in the TMA (p = 0.049). d Scatterplot demonstrating the correlation between average centrosome number
and proliferation, as assessed by Ki67 staining
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0.001; Fig. 2e) than those without CA. Furthermore,
these patients also had worse breast cancer-specific mor-
tality (P = 0.003; Fig. 2f ). Our findings led us to
hypothesize that high-CA tumors may provide useful
prognostic data in addition to providing a biologic rea-
son for aggressive breast cancers. To be clinically useful,
CA would need to indicate risk that is not captured with
currently available clinical factors such as tumor stage,
grade, and subtype. To test this, we performed Cox pro-
portional hazards modeling (Additional file 1: Table S2).
This analysis demonstrated that stage and hormone re-
ceptor status were the strongest predictors of OS and
RFS. When corrected for these, CA is not an independ-
ent predictor of OS or RFS. Although CA does not pro-
vide a clinical factor independent of known risk factors,
it nevertheless may provide a biological explanation for
how tumors advance in grade and stage.
To survey additional centrosome defects, we observed
aberrations in centrosome shape, size, and patterning
(Additional file 1: Figure S2). Centrosome clustering was
observed in 58 % of tumors versus 13 % of normal sam-
ples. Centrosome speckling (clusters with >5 centrosomes)
was observed in 23 % of tumors versus 7 % of normal
samples, and irregular centrosome shapes in 41 % of tu-
mors versus 20 % of normal samples (this relatively high
incidence of abnormal shapes in normal samples likely
represents staining artifact). What we term centrosome
speckling has been described by others as sand-like cen-
trosomes [12]. We did not observe worse clinical out-
comes with atypically shaped centrosomes or centrosome
speckling, although centrosome clustering correlated with
significantly worse OS (P = 0.009) and RFS (P = 0.030).
Centrosome clustering has been proposed as a mechanism
by which cells with CA are able to divide with pseudo-
bipolar spindles [36, 37], although it is unclear whether
the interphase clustering observed here would correspond
with clustering during mitosis.
Doubling events as a common cause of centrosome
amplification
One potential mechanism leading to CA is cell-doubling
events (e.g. cytokinesis failure, cell-cell fusion). If cell
doubling represented the primary cause of CA in breast
cancer, we would expect a strong correlation between CA
and increased cell ploidy. Therefore, we evaluated how
CA correlates with high tumor ploidy, as determined by
Fig. 2 Centrosome amplification is associated with adverse clinical factors. Centrosome amplification correlates with stage (a; p< 0.01), grade (b; p< 0.01),
and subtype (c; p< 0.01). Dots represent each patient with bars representing the average ± SE. HR = hormone receptor. d-f Tumors were considered to
have CA if the average number of centrosomes per cell, as assessed by pericentrin staining, was greater than 2. Centrosomes were assessed with
pericentrin staining. All-cause overall survival (d), recurrence-free survival (e), and breast cancer-specific overall survival (f) are reduced in patients whose
tumors demonstrated CA compared to those that did not. Log rank tests were used to calculate p-values
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6-chromosome FISH in 354 breast tumors. Ploidy ranged
from 1.43 to 8.75 with a median of 2.08. We find that CA
strongly correlates with ploidy (P = 0.006; Fig. 3a). Further,
after dividing patients by CA (defined as >2 centrosomes
per cell), tumors with CA had significantly greater ploidy
(Fig. 3b). To verify these findings, analyses were repeated
using a more stringent definition for centrosomes: the
overlap of pericentrin and polyglutamylated tubulin,
which represents the overlap of PCM and centriole
markers, respectively [30, 31]. Using these criteria, CA still
correlated with ploidy (Additional file 1: Figure S3). These
data provide evidence that CA and whole genomic ampli-
fications occur in concert in incipient tumor cells, suggest-
ing that genome doubling events occur commonly in
breast cancer oncogenesis.
To estimate what percentage of CA events arise
from doubling events, we calculated the percent of
tumors with CA (average centrosome number >2)
that also had elevated ploidy (>3). This revealed that
at least 15 % of CA events arose from doubling
events (Fig. 3c). However, this method is likely to
underestimate the true percentage of CA events that
arise from doubling events because cells that originate
after genome doubling can subsequently lose chromo-
somes [38, 39].
Centrosome amplification as a common cause of
chromosomal instability
CA can lead to multipolar cell division or lagging chro-
mosomes through induction of merotelic attachments
on focused bipolar spindles, resulting in chromosomal
instability (CIN) [39]. Therefore, we examined the rela-
tionship between CA and CIN. CIN was calculated as
the percent of cells within a tumor with a non-modal
number of chromosomes, averaged for 6 chromosomes.
44.7 % of breast tumors have CIN compared to 9.1 % of
normal breast samples. Patients whose tumors displayed
CIN had worse breast cancer-related overall survival
(Additional file 1: Figure S3). CA correlated positively
with CIN (Fig. 3d, P < 0.001). After dividing the patients
into two groups based the presence of CA, as done for
survival analyses, tumors with higher CA had signifi-
cantly elevated CIN (Fig. 3e). These data support the hy-
pothesis that CA is a common cause of CIN in breast
cancer. In addition, we found a strong positive correl-
ation between ploidy and CIN (Fig. 3f ).
Pericentriolar material fragmentation is a marker of
aggressive tumors
As done above for CA and ploidy analysis, we repeated
other analyses using the more stringent definition of
Fig. 3 Centrosome amplification correlates with high ploidy and high CIN. a Centrosome number correlates with ploidy. b-e Breast tumors were
divided into two groups based on the presence or absence of CA, which was defined as having an average of >2 centrosomes per cell, as in
Figure 2. Tumors with CA had higher average ploidy, as assessed by 6-chromosome FISH (b), polyploidy (c), and CIN, as assessed by the average
non-modal chromosome number from FISH (e). d Centrosome number correlated with CIN. f Ploidy and CIN also correlated.
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pericentrin and polyglutamylated tubulin overlap. Simi-
lar to our analysis based on pericentrin staining alone,
CA defined by the overlap of pericentrin and polygluta-
mylated tubulin was more pronounced in triple negative
breast cancer and cancers with higher histological grade
(Additional file 1: Figure S4A-D). Patients with CA had
worse overall and recurrence-free survival (Additional
file 1: Figure S4E-G). Furthermore, CA as defined by
these criteria also demonstrated a significant correlation
with ploidy and CIN (Additional file 1: Figure S5A-D).
In summary, we observed similar findings whether cen-
trosomes were defined using solely pericentrin or using
the overlap of pericentrin and polyglutamylated tubulin.
Although centrioles are surrounded by PCM in nor-
mal cells, ~1/3 of cells in normal samples had PCM
without detectable centrioles, suggesting that only a
subset of centrioles were labeled with the polygluta-
mylated tubulin antibody. However, compared with
normal samples, tumors more frequently had pericen-
trin foci that lacked co-staining with polyglutamylated
tubulin. An average of 78 % of pericentrin foci con-
tained this centriolar marker in normal samples com-
pared to an average of 46 % in breast tumors. 302
out of 362 breast cancer cases had a percentage lower
than 78 %, suggesting a true loss of this centriole
marker in some breast tumors. These findings suggest
that either these tumor centrioles lack polyglutamy-
lated tubulin, or that acentriolar centrosomes are a
bona fide characteristic of many human breast can-
cers. Acentriolar centrosomes have been reported pre-
viously in cancer cells and are thought to result from
PCM fragmentation [19, 40]. Additionally, acentriolar
centrosomes were more common in the triple-
negative breast cancer subtype and correlated with
advanced stage and grade (Fig. 4a-c), although there
was no significant correlation with worse clinical out-
comes (Fig. 4d-e; P = 0.202 for overall survival and P
= 0.133 for recurrence-free survival). Nevertheless,
these findings indicate that PCM fragmentation is po-
tentially a marker of more aggressive tumors.
Fig. 4 Pericentriolar material (PCM) fragmentation is more prevalent in advanced tumors. a-c The average percent of centrosomes (as indicated by
pericentrin) without centrioles (as indicated by polyglutamylated tubulin) were plotted based on subtype (a), stage (b) and grade (c). a T-tests were used
to compare averages for each breast cancer subtype to normal breast. HR+ = hormone receptor (ER and/or PR) positive and HER2 nonamplified;
HER2+ =HER2 amplified; TNBC = triple negative breast cancer. b-c ANOVA was used to analyze differences across stage and grade; the asterisk indicates P
< 0.05 for these statistical tests. d-e Overall survival (d) and recurrence-free survival (e) were plotted using the Kaplan Meier method with the cutoff being
the median percentage of centrosomes without centrioles. Log rank tests were used to determine P values
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Centrosome amplification causes high-grade features
Because there was a strong correlation of CA with
poorly differentiated tumors (grade 3) in our study and
others [6–8], we hypothesized that CA induces cellular
de-differentiation. To test this, we utilized doxycycline-
inducible PLK4 in MCF10A and RPE cell lines [24, 41],
in which the overexpression of PLK4 results in CA
(Fig. 5a, d), and subsequently looked at markers of dif-
ferentiation. Breast cancer cells that express less CD24
and more CD44 are more de-differentiated and more
stem cell-like [42–44]. These cells may also have en-
hanced metastatic potential [45]. We analyzed CD24 and
CD44 by flow cytometry after inducing CA in MCF10A
cells, and found that this significantly decreased CD24
and increased CD44 (Fig. 5b-c). To ensure this was not
an effect of doxycycline or of PLK4 expression inde-
pendent of centrosome amplification, we employed a
doxycycline-inducible PLK41-608 cell line in which this
kinase is expressed without amplifying centrosomes due
to lack of a critical localization domain. We did not ob-
serve markers of de-differentiation with doxycycline in
this control (Fig. 5c). To validate this finding, we
employed a second cell line, immortalized retinal pig-
ment epithelial (RPE) cells, for which cytokeratin profiles
can reveal differentiation status. More de-differentiated
cells express excess cytokeratins 7 and 19 and less cyto-
keratin 18 [46–49]. We assessed expression of these 3 cyto-
keratins by qRT-PCR, finding that RPE cells with CA
express more cytokeratins 7 and 19, but less cytokeratin 18
(Fig. 5e), which is consistent with a de-differentiated state.
The Nottingham grading scale uses the following
three criteria to determine the differentiation status of
a tumor: (1) the amount of gland formation, (2) nu-
clear pleomorphisms, and (3) mitotic figures [50, 51].
To address whether CA is sufficient to impart these
characteristics, we first observed which tumors dem-
onstrated glandular/tubular structures in at least two
of three histologic regions examined. Indeed, tumors
from the TMA without tubule formation had greater
CA (Fig. 5f ). With regard to the second criterion,
previous work has shown cells with CA can exhibit
multipolar spindles and other nuclear pleomorphisms,
and this is seen in vitro as well (Fig. 5g). For the
third criterion, it has already been demonstrated that
cells with CA proliferate more slowly [24, 52], which
would tend to cause lower grade tumors; however,
numerical CA positively correlates with Ki67 status in
our data set (Pearson r = 0.3106, p < 0.001, Fig. 1d)
suggesting that CA does not cause tumor cells to exit
the cell cycle. Furthermore, it has been demonstrated
that cells with CA take longer to complete mitosis
due to multipolar spindle formation [53], which could
explain why more mitotic figures are seen in tumors
with CA. Taken together, these data support the idea
that CA directly or indirectly imparts high-grade fea-
tures to tumors, leading to worse clinical outcomes.
Discussion
Our findings provide important insight into the origin,
frequency, and the clinical correlates of CA in human
breast cancer. CA was previously reported in small sam-
ple sizes to be a hallmark found in diverse cancer types
[3], and is often found early in carcinogenesis, including
in precursor lesions of breast cancer [22]. Likewise, we
find that CA is common in our cohort of 362 breast
cancer patients. CA correlates with increasing grade and
stage, and CA was more pronounced in triple negative
and HER2 amplified subtypes, consistent with past ob-
servations in smaller patient cohorts [6–13]. Further, CA
confers worse outcomes, which can be explained by the
aggressive characteristics of cancers with CA, including
advanced stage and grade. Intriguingly, CA is sufficient
to induce high-grade phenotypes in human epithelial
cells, including those of breast origin. This can explain
why tumors that originate with CA have de-
differentiated phenotypes that presage worse clinical
outcomes. Additionally, CA can cause CIN, leading to
rapid evolution of tumors into more aggressive
phenotypes.
Our data provide the first evidence for the origin of
CA in breast cancer. The data indicate that at least 15 %
of cases of CA in human breast cancer arose by a doub-
ling event, such as cytokinesis failure or cell-cell fusion.
However, our method likely underestimated the true
percentage of CA from doubling events because CA can
lead to further chromosome loss, and tetraploidy buffers
the risk of haploinsufficiency [38, 39]; hence some CA
cancers with near-diploid genomes could have originated
in a doubling event. To more definitively answer this
question regarding the relative contributions of mecha-
nisms leading to CA, a large tumor cohort could be
probed for a marker of mature centrioles, such as
CEP170 or centrobin. Cells with de novo centrosome
amplification should have a single CEP170-positive
centrosome, whereas tumor cells with multiple CEP170-
positive centrosomes are more consistent with doubling
events, in which two mature centrosomes would be
inherited.
PCM fragmentation has been proposed as a mechan-
ism by which CA can occur [19, 40, 54]. Indeed, we
found centrioles absent from a sizeable proportion of
centrosomes in the tumor samples in our TMA. This
suggests that the regulation of recruitment of centro-
some proteins is just as important as the regulation of
centriole duplication for proper centrosome function.
Excess PCM or PCM fragmentation may result in cells
that are likely to undergo multipolar mitoses and gener-
ate daughter cells with altered karyotypes. Many of these
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daughter cells generated from multipolar divisions will
not be viable but will promote diversity for evolutionary
selection. We found that an increased percentage of
acentriolar centrosomes correlated with adverse clinical
features, suggesting that PCM fragmentation is more
common in more aggressive tumors.
Previous studies have provided conflicting information
about how centrosome number and size correlate with
aneuploidy and CIN in breast cancer, with some studies
supporting the relationship [22], and others finding no
association [55]. Here we quantified a greater number of
chromosomes with FISH on a larger patient cohort and
Fig. 5 (See legend on next page.)
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found a strong correlation of CA with both CIN and aneu-
ploidy. This is consistent with mechanistic studies that il-
lustrate that CA can cause CIN and aneuploidy [6, 14, 15].
The strong correlation between CA and ploidy suggests
that CA can occur in many breast cancers from prior cell
doubling events, although it is unclear whether this origi-
nates from failed cell division, cell-cell fusion, or other
mechanism such as endoreduplication. Furthermore, we
found a strong positive correlation between ploidy and
CIN, consistent with the previous suggestion that cells with
higher ploidy can better tolerate CIN and buffer the dele-
terious effects of CIN [38]. However, there were a number
of cases (approximately 18 %) in which CIN did not correl-
ate with CA. First amongst these was a high CA, low CIN
group, in which centrosome clustering may be occurring;
clustering has been described previously as a way that the
cell prevents multipolar spindle formation [21, 36, 56], al-
though this can still result in chromosome missegregation
[39]. In a second group with low CA and high CIN, another
mechanism of generating CIN is operating, such as im-
paired checkpoint function [19–21].
Advantages of our methods include a large cohort
of breast tumor samples with survival data, evaluation
of 6 chromosomes by FISH for analysis of aneuploidy
and CIN, and use of the overlap of PCM and centri-
ole markers to characterize acentriolar centrosomes
and PCM fragmentation. This allowed us to establish
how CIN and ploidy correspond with centrosome
number in hundreds of breast tumors. A potential
limitation to this study is dependence on single-
section analysis of histological samples, which under-
estimate CA and overestimate CIN through sectioning
artifact. However, the inclusion of triplicate punch bi-
opsies per patient and normal breast samples help to
alleviate this concern. It is possible that larger cancer
cells could suffer disproportionate underestimation of
CA than normal cells; however this does not explain
our finding that CA is commonly found in larger
high-grade tumor cells. Nevertheless, our results pro-
vide quantitative comparisons among breast cancer
types and shed important insight into the causes and
consequences of CA in human breast cancer.
Conclusions
CA is a common feature of human breast cancers that pre-
sages worse clinical outcomes but is not an independent
predictor of survival. CA arises by multiple mechanisms,
most predominantly by doubling events and PCM frag-
mentation. PCM fragmentation may represent a marker of
high-risk cancers. In human cancer CA is associated with a
high-grade phenotype and loss of genetic stability. These
factors lead to the aggressive phenotypes of cancers with
high CA. It may be possible to interrupt these phenotypes
with specific drugs targeting centrosome amplification,
such as recently discovered inhibitors of PLK4 [57–59].
Availability of supporting data and materials
All of the data on which the conclusions of the paper
rely are included in the main figures or supplementary
figures.
Additional file
Additional file 1: Table S1. Patient characteristics. Table S2. Hazard ratios
from multivariate analysis. Table S3. Sequences of primers used for qRT-PCR.
Figure S1. Distribution of average centrosome number per cell in the breast
cancer patients represented in our TMA. Figure S2. Correlations between
centrosome amplification and nodal status, patient age, and tumor size.
Figure S3. Centrosome clustering but not structural abnormalities correlate
with worse outcomes in breast cancer. Figure S4. CIN is prognostic of worse
breast cancer-related survival. Figure S5. Centrosome amplification correlates
with adverse clinical factors.
Figure S6. CA correlates with higher ploidy and CIN. (DOCX 6223 kb)
Abbreviations
CA: centrosome amplification; CIN: chromosomal instability; HER2: human
epidermal growth factor receptor 2; HR: hormone receptor; OS: overall
survival; PCM: pericentriolar material; RFS: recurrence-free survival;
TNBC: triple negative breast cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RAD participated in the study’s conception and design, carried out the
experiments, analyzed the data, and drafted the manuscript. LMZ carried out the
experiments and analyzed the data. CK carried out the experiments and analyzed
the data. JL carried out the experiments and analyzed the data. BAW contributed
to the conception and design, analyzed the data, and drafted the manuscript.
MEB conceived of the study, analyzed the data, and drafted the manuscript.
All authors read, edited, and approved the final manuscript.
(See figure on previous page.)
Fig. 5 Centrosome amplification induces dedifferentiation. a Overexpression of PLK4 using doxycycline-inducible MCF10A cell line [24] results in
CA after 48 hours of doxycycline treatment. PLK4608 overexpresses a truncated form (amino acids 1-608) that contains the kinase domain but does
not result in CA. Blue = DNA, yellow = overlap of pericentrin and gamma tubulin. b, c Flow cytometry analysis of CD24 and CD44 expression in
MCF10A cells using PE-conjugated antibodies after 48 hours of doxycycline treatment. b Mean channel fluorescence (FL2) was normalized within
cell lines (i.e. either PLK4WT or PLK4608). c Bars represent the average ± SE of 3 independent experiments. d Overexpression of PLK4 using
doxycycline-inducible RPE cell line [41] results in CA. e qRT-PCR analysis of cytokeratins 7, 18, and 19 normalized to 3 housekeeping genes
(RRN18S, GAPDH, ACTB) in RPE cells. Bars represent average values of 2^-ΔΔCt from 3 independent experiments. f Tumors in the TMA with tubule
formation in 2 of the 3 tumor regions examined were compared to tumors without tubule formation. Representative images demonstrate how
the scoring was performed. Blue = DNA, green = pericentrin. g Representative images of normal and pleomorphic nuclei seen in RPE and MCF10A
cell lines treated with doxycycline. The bar graphs demonstrate the average percent of pleomorphic nuclei in each condition from 3 independent
experiments. Blue = DNA, green = pericentrin. *P < 0.05. Scale bars = 5 μm
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